secwatch.observer — SEC 8-K summary
======================================

Issuer:     Imunon, Inc. (IMNN)
CIK:        0000749647
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001493152-23-027452
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Imunon Q2 net loss narrows to $5.6M; cash $24.1M; on track for COVID IND Q1 2024
--------------------------------------------------------------------------------

- Net loss Q2 2023 $5.6M ($0.61/sh) vs $6.0M ($0.87/sh) in Q2 2022; operating expenses down 10% YoY.
- Cash and investments $24.1M at June 30, 2023; plus planned $1.8M from NOL sales; expected to fund operations through 2024.
- On track to submit IND for seasonal COVID-19 vaccine (IMNN-101) in Q1 2024; FDA confirmed platform acceptability.
- Unveiled new cGMP manufacturing facility at HudsonAlpha to support R&D and lower costs.
- Preclinical data show PlaCCine vaccines elicit durable T-cell responses > 14 months, higher than mRNA vaccine.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/749647/000149315223027452/0001493152-23-027452-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/749647/000149315223027452/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-027452

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer